Related Experiment Video

Updated: Jul 15, 2026

A Model of Chronic Nutrient Infusion in the Rat
08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue

H C Lee1, S J Kim, K S Kim

  • 1Department of Internal Medicine, Yonsei University, College of Medicine, Seoul, Korea. endohclee@yumc.yonsei.ac.kr

Nature
|December 2, 2000
PubMed

Insights

A novel gene therapy using a recombinant adeno-associated virus (rAAV) expressing a single-chain insulin analogue (SIA) has successfully induced long-term diabetes remission in animal models. This breakthrough offers potential for a cure for autoimmune diabetes.

Area of Science:

  • Biotechnology
  • Endocrinology
  • Gene Therapy

Background:

  • Type 1 diabetes results from autoimmune destruction of insulin-producing beta cells.
  • Current therapies like insulin treatment may not adequately control blood glucose levels.
  • Achieving a permanent cure for autoimmune diabetes remains a significant challenge.

Purpose of the Study:

  • To develop a novel gene therapy for autoimmune diabetes.
  • To assess the efficacy of a single-chain insulin analogue (SIA) delivered via rAAV.
  • To evaluate long-term diabetes remission and safety in preclinical models.

Main Methods:

  • Utilized a recombinant adeno-associated virus (rAAV) vector.
  • Engineered the vector to express a single-chain insulin analogue (SIA) under a glucose-responsive promoter (LPK).
  • Tested the rAAV-LPK-SIA construct in streptozotocin-induced diabetic rats and autoimmune diabetic mice.

Main Results:

  • The rAAV-LPK-SIA gene construct successfully produced biologically active SIA.
  • Diabetes remission was achieved in both rat and mouse models for a prolonged duration.
  • No apparent side effects were observed during the study.

Conclusions:

  • SIA gene therapy demonstrated significant therapeutic potential for autoimmune diabetes.
  • This approach may offer a viable alternative to conventional diabetes treatments.
  • Further research may lead to a potential cure for human autoimmune diabetes.

More Related Videos

An In Ovo Model for Testing Insulin-mimetic Compounds06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro14:18

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro

Published on: October 13, 2023

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...